• Admin Login
    View Item 
    •   Home
    • Research Institute in Healthcare Science
    • Research Institute in Healthcare Science
    • View Item
    •   Home
    • Research Institute in Healthcare Science
    • Research Institute in Healthcare Science
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of WIRECommunitiesTitleAuthorsIssue DateSubmit DateSubjectsTypesJournalDepartmentPublisherThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsTypesJournalDepartmentPublisher

    Administrators

    Admin Login

    Local Links

    AboutThe University LibraryOpen Access Publications PolicyDeposit LicenceCOREWIRE Copyright and Reuse Information

    Statistics

    Display statistics

    Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Seymour, Leonard W.
    Ferry, David R.
    Anderson, David
    Hesslewood, Stuart
    Julyan, Peter J.
    Poyner, Richard
    Doran, Jayne
    Young, Annie M.
    Burtles, Sally
    Kerr, David J.
    Issue Date
    2002
    
    Metadata
    Show full item record
    Abstract
    PURPOSE: Preclinical studies have shown good anticancer activity following targeting of a polymer bearing doxorubicin with galactosamine (PK2) to the liver. The present phase I study was devised to determine the toxicity, pharmacokinetic profile, and targeting capability of PK2. PATIENTS AND METHODS: Doxorubicin was linked via a lysosomally degradable tetrapeptide sequence to N-(2-hydroxypropyl)methacrylamide copolymers bearing galactosamine. Targeting, toxicity, and efficacy were evaluated in 31 patients with primary (n = 25) or metastatic (n = 6) liver cancer. Body distribution of the radiolabelled polymer conjugate was assessed using gamma-camera imaging and single-photon emission computed tomography. RESULTS: The polymer was administered by intravenous (i.v.) infusion over 1 hour, repeated every 3 weeks. Dose escalation proceeded from 20 to 160 mg/m(2) (doxorubicin equivalents), the maximum-tolerated dose, which was associated with severe fatigue, grade 4 neutropenia, and grade 3 mucositis. Twenty-four hours after administration, 16.9% +/- 3.9% of the administered dose of doxorubicin targeted to the liver and 3.3% +/- 5.6% of dose was delivered to tumor. Doxorubicin-polymer conjugate without galactosamine showed no targeting. Three hepatoma patients showed partial responses, with one in continuing partial remission 47 months after therapy. CONCLUSION: The recommended PK2 dose is 120 mg/m(2), administered every 3 weeks by IV infusion. Liver-specific doxorubicin delivery is achievable using galactosamine-modified polymers, and targeting is also seen in primary hepatocellular tumors.
    Citation
    Journal of Clinical Oncology, 20(6): 1668-1676
    Publisher
    American Society of Clinical Oncology
    Journal
    Journal of Clinical Oncology
    URI
    http://hdl.handle.net/2436/29455
    PubMed ID
    11896118
    Additional Links
    http://jco.ascopubs.org/cgi/content/full/20/6/1668
    Type
    Journal article
    Language
    en
    ISSN
    0732-183X
    Collections
    Research Institute in Healthcare Science

    entitlement

    Related articles

    • Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.
    • Authors: Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J
    • Issue date: 1999 Jan
    • Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine.
    • Authors: Julyan PJ, Seymour LW, Ferry DR, Daryani S, Boivin CM, Doran J, David M, Anderson D, Christodoulou C, Young AM, Hesslewood S, Kerr DJ
    • Issue date: 1999 Feb 22
    • Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent.
    • Authors: Hopewel JW, Duncan R, Wilding D, Chakrabarti K
    • Issue date: 2001 Sep
    • First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
    • Authors: Schöffski P, Delord JP, Brain E, Robert J, Dumez H, Gasmi J, Trouet A
    • Issue date: 2017 Nov
    • Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    • Authors: Hong RL, Tseng YL
    • Issue date: 2001 May 1
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.